COMBI.ST
Price:
$2.47
Market Cap:
$48.91M
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Industry
Biotechnology
IPO Date
2015-05-25
Stock Exchange
STO
Ticker
COMBI.ST
According to CombiGene AB (publ)’s latest financial reports and current stock price. The company's current ROE is -50.67%. This represents a change of 289.03% compared to the average of -13.02% of the last 4 quarters.
The mean historical ROE of CombiGene AB (publ) over the last ten years is -70.06%. The current -50.67% ROE has changed -27.68% with respect to the historical average. Over the past ten years (40 quarters), COMBI.ST's ROE was at its highest in in the December 2021 quarter at 36.30%. The ROE was at its lowest in in the March 2020 quarter at -69.72%.
Average
-70.06%
Median
-62.86%
Minimum
-212.44%
Maximum
13.25%
Discovering the peaks and valleys of CombiGene AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 768.08%
Maximum Annual ROE = 13.25%
Minimum Annual Increase = -130.74%
Minimum Annual ROE = -212.44%
Year | ROE | Change |
---|---|---|
2024 | -62.70% | 104.72% |
2023 | -30.63% | 768.08% |
2022 | -3.53% | -126.63% |
2021 | 13.25% | -130.74% |
2020 | -43.08% | -55.41% |
2019 | -96.61% | 50.33% |
2018 | -64.27% | -53.28% |
2017 | -137.56% | -35.25% |
2016 | -212.44% | 237.11% |
2015 | -63.02% | 271.69% |
The current ROE of CombiGene AB (publ) (COMBI.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.28%
5-year avg
-25.34%
10-year avg
-70.06%
CombiGene AB (publ)’s ROE is greater than Sprint Bioscience AB (publ) (-184.99%), greater than Bio-Works Technologies AB (publ) (-81.73%), greater than Nanologica AB (publ) (-164.35%), greater than 2cureX AB (publ) (-237.83%), greater than Kancera AB (publ) (-66.81%), greater than BioInvent International AB (publ) (-49.84%), greater than Oncopeptides AB (publ) (-294.46%), greater than Acarix AB (publ) (-97.75%),
Company | ROE | Market cap |
---|---|---|
-184.99% | $48.24M | |
-81.73% | $127.94M | |
-164.35% | $96.31M | |
-237.83% | $104.69M | |
-66.81% | $197.78M | |
-49.84% | $2.36B | |
-294.46% | $469.01M | |
-97.75% | $393.58M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CombiGene AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CombiGene AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is CombiGene AB (publ)'s ROE?
How is the ROE calculated for CombiGene AB (publ) (COMBI.ST)?
What is the highest ROE for CombiGene AB (publ) (COMBI.ST)?
What is the 3-year average ROE for CombiGene AB (publ) (COMBI.ST)?
What is the 5-year average ROE for CombiGene AB (publ) (COMBI.ST)?
How does the current ROE for CombiGene AB (publ) (COMBI.ST) compare to its historical average?